Syncona delivers positive full-year return despite volatile biotech market
- Positive NAV return despite weak biotech sector- Balance sheet strengthened following Gyroscope sale- Plans to deploy more cash Life sciences investment trust Syncona (SYNC) reported a largely unchanged net asset value for the...
16 June 2022